StudyFinder

A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated with Lonapegsomatropin (SkyPASS)

Recruiting

The purpose of this study is to evaluate the long-term safety and effectiveness of Skytrofa treatment in children growth hormone deficiency. Patient care will follow the normal treatment practices at the clinic. No additional visits will be performed beyond the usual clinical practice.

I'm interested
Visit the Study Website

Male or Female
Up to 18 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 1 to 18 years old
• on treatment with SKYTROFA (lonapegsomatropin)
Exclusion Criteria:

• participating in any interventional clinical study for short stature

Drug: No intervention

Diabetes & Endocrine, Rare Diseases, Rare Diseases, Rare Diseases

growth hormone and growth hormone deficiency

Brad Miller - mille685@umn.edu
Brad Miller, MD, PhD
SITE00002030
See this study on ClinicalTrials.gov

Back